When the Food and Drug Administration cleared Apple’s smartwatch app that alerts people if they may be at risk of an irregular heart rhythm called atrial fibrillation, scientists had one big question — how good is it?

Only a bit of data has been released about the device. In September, the FDA told STAT that the company collected much of the data supporting the app during its Heart Study, a nearly yearlong clinical trial it funded, based at Stanford University.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy